A high-performance liquid chromatographic method was applied to the determination of gamabufotalin, telocinobufagin, bufotalin, cinobufotalin, bufalin, cinobufagin and resibufogenin in three traditional Chinese medicinal preparations containing ChanSu. The compounds were separated on a YMC-C18 column (250 × 4.6 mm, 5 um) with a gradient of acetonitrile and 0.3% aqueous acetic acid ( v / v) at a flow rate of 0.8 mL min−1 and detected at 296 nm. Complete separation was obtained within 35 min for the seven bufadienolides. The calibration curves showed good linearity (r2 > 0.999) within the test range. The recovery was 95.5% - 105.9%. The assay could simultaneously determine seven major bufadienolides of the three Chinese medicinal preparations of ChanSu in 35 min. The results obtained suggested that the developed HPLC assay could be comprehensively utilized for the quality control of the three traditional Chinese medicinal preparations of ChanSu used in the clinic.
Background:
The objective of this study is to systematically evaluate the efficacy and safety of the calcitonin gene-related peptide (CGRP) receptor antagonist ubrogepant for the treatment of acute migraine.
Methods:
Randomized controlled trials (RCTs) of ubrogepant for treatment of acute migraine were identified in PubMed, MEDLINE, EMBASE, and the Cochrane Library from database establishment to June 2020; we also searched ClinicalTrials.gov manually during the same period. Then, RevMan 5.3 software was used to perform a meta-analysis on each outcome measure.
Results:
A total of 5 RCTs involving 4903 patients were included; there were 3358 cases in the ubrogepant group and 1545 cases in the placebo group. The meta-analysis showed the following results: at 2 hours postdose, the percentages of participants reporting pain relief and the absence of photophobia, nausea, and phonophobia were significantly higher in the ubrogepant group than in the placebo group (odds ratio [OR] = 1.71, 95%CI: 1.48–1.97, P < .00001; OR = 1.33, 95%CI: 1.22–1.45, P < .00001; OR = 1.07, 95%CI: 1.03–1.11, P = .0006; OR = 1.21, 95%CI: 1.14–1.28, P < .00001). The incidence of common adverse events was similar between the 2 groups (P > .05).
Conclusion:
Ubrogepant is effective and safe for the treatment of acute migraine.
Registration number:
PROSPERO CRD42019145286.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.